Kwality Pharmaceuticals Limited Stock Price Today (NSE: KPL)
Fundamental Score
Kwality Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kwality Pharmaceuticals Limited share price today is ₹3356.00, down 2.17% on NSE/BSE as of 16 September 2026. Kwality Pharmaceuticals Limited (KPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.81K (Cr). The 52-week high for KPL share price is ₹3798.90 and the 52-week low is ₹3137.00. At a P/E ratio of 41.35x, KPL is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 22.82% and a debt-to-equity ratio of 0.39.
Kwality Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Kwality Pharmaceuticals Limited share price chart: 16.95% return over the past month. 52-week high ₹3798.90, 52-week low ₹3137.00.
Kwality Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3420.10 | ₹3477.20 | ₹3137.00 | ₹3356.00 | 82.02K (Cr) | |
| ₹3700.00 | ₹3786.40 | ₹3392.50 | ₹3430.60 | 57.73K (Cr) | |
| ₹3500.10 | ₹3694.00 | ₹3422.30 | ₹3643.30 | 42.96K (Cr) | |
| ₹3619.90 | ₹3619.90 | ₹3464.00 | ₹3511.60 | 18.18K (Cr) | |
| ₹3678.90 | ₹3798.90 | ₹3552.50 | ₹3577.00 | 42.95K (Cr) | |
| ₹3443.00 | ₹3710.00 | ₹3442.90 | ₹3661.40 | 1.62L (Cr) | |
| ₹3312.30 | ₹3428.30 | ₹3285.60 | ₹3411.20 | 22.59K (Cr) | |
| ₹3350.00 | ₹3421.70 | ₹3211.10 | ₹3285.50 | 49.24K (Cr) | |
| ₹3428.00 | ₹3445.00 | ₹3290.20 | ₹3351.70 | 21.88K (Cr) | |
| ₹3388.90 | ₹3425.00 | ₹3324.10 | ₹3390.10 | 25.59K (Cr) |
Kwality Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹3299.30 | ₹3798.90 | ₹3137.00 | ₹3356.00 | +1.72% | |
| ₹2573.10 | ₹3744.00 | ₹2476.00 | ₹3277.00 | +27.36% | |
| ₹2839.70 | ₹2849.35 | ₹2512.25 | ₹2586.00 | -8.93% | |
| ₹2389.70 | ₹2889.00 | ₹2180.00 | ₹2802.10 | +17.26% | |
| ₹1582.30 | ₹2351.00 | ₹1466.20 | ₹2310.35 | +46.01% | |
| ₹1350.00 | ₹1782.00 | ₹1335.55 | ₹1581.45 | +17.14% | |
| ₹1436.00 | ₹1740.00 | ₹1270.00 | ₹1306.35 | -9.03% | |
| ₹1079.95 | ₹1599.00 | ₹1032.30 | ₹1555.85 | +44.07% | |
| ₹1120.00 | ₹1188.00 | ₹1020.00 | ₹1065.30 | -4.88% | |
| ₹929.00 | ₹1200.00 | ₹851.95 | ₹1108.35 | +19.31% | |
| ₹898.00 | ₹1010.45 | ₹828.80 | ₹931.45 | +3.72% | |
| ₹910.05 | ₹935.00 | ₹840.00 | ₹893.25 | -1.85% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kwality Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kwality Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KPL across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (22.82%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.35%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (74.60%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.81%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.94% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (35.00% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (35.00% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (9.23x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.67)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (54.87%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 41.35x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (13.19x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Institutional Interest (FII+DII: 3.15%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kwality Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kwality Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
66.1/100 | ₹3356.00₹3356 | ₹2810.23₹2810.23 | 41.35Average 41.4 Average | 22.82%Excellent 22.82% Excellent | 24.25%Excellent 24.25% Excellent | 0.39Excellent 0.4 Excellent | 35.00%Excellent 35.00% Excellent | 13.94%Good 13.94% Good | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1867.00₹1867 | ₹447949.31₹447949.31 | 37.04Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9443.00₹9443 | ₹250239.50₹250239.50 | 85.68Average 85.7 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4925.00₹4925 | ₹166691.55₹166691.55 | 78.67Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1130.90₹1131 | ₹112863.82₹112863.82 | 25.20Average 25.2 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.20₹1370 | ₹110691.61₹110691.61 | 32.83Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1935.00₹1935 | ₹104538.38₹104538.38 | 95.51Average 95.5 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2107.20₹2107 | ₹96351.72₹96351.72 | 17.41Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1672.10₹1672 | ₹96212.63₹96212.63 | 26.13Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.80₹1146 | ₹95674.30₹95674.30 | 29.61Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2276.90₹2277 | ₹94035.97₹94035.97 | 46.01Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447949.31 Cr
- Divi's Laboratories Limited share price250239.50 Cr
- Torrent Pharmaceuticals Limited share price166691.55 Cr
- Zydus Lifesciences Limited share price112863.82 Cr
- Cipla Limited share price110691.61 Cr
Kwality Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for KPL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹38.36 | ₹1108.35 | 28.9x |
| FY 2024 | ₹22.76 | ₹866.80 | 38.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Kwality Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for KPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
35.81%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
74.60%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.94%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
35.00%
Compounded annual net profit growth over 5 years
Kwality Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KPL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kwality Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Kwality Pharmaceuticals Limited (KPL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Kwality Pharmaceuticals Limited
About KPL (Kwality Pharmaceuticals Limited)
Kwality Pharmaceuticals Ltd is a dynamic and multifaceted pharmaceutical enterprise dedicated to crafting and distributing a wide spectrum of high-quality medicinal formulations. W...ith a commitment to innovation and patient well-being, the company meticulously develops and manufactures its products to meet stringent global standards. From advanced research and development initiatives to sophisticated manufacturing processes, Kwality Pharmaceuticals strives to deliver reliable and effective healthcare solutions across diverse therapeutic areas. The company operates with a core focus on integrity, transparency, and ethical practices, ensuring that its products contribute positively to the health and wellness of communities worldwide. Kwality Pharmaceuticals is poised to address evolving healthcare needs with a portfolio of pharmaceutical offerings. Kwality Pharmaceuticals' robust manufacturing capabilities are reflected in its diverse range of dosage forms. The company excels in producing liquid orals, catering to patients who prefer easy administration. Dry syrups and powders for oral suspension offer flexible dosing options, while tablets and capsules remain staples for convenient consumption. For specialized needs, Kwality Pharmaceuticals manufactures sterile powders for injection, along with small volume parentals in both liquid and lyophilized forms. The company further demonstrates its versatility with pre-filled syringes, ointments, creams, and ophthalmic preparations such as eye and ear drops. Kwality Pharmaceuticals also produces sanitizers, suppositories, injectable vials and ampoules. Underpinning Kwality Pharmaceuticals' operations is a steadfast dedication to quality control and regulatory compliance. The company adheres to stringent Good Manufacturing Practices (GMP) across all its facilities, ensuring that every product meets the highest benchmarks for safety, efficacy, and purity. Through continuous monitoring, rigorous testing, and ongoing improvement initiatives, Kwality Pharmaceuticals maintains the integrity of its manufacturing processes and reinforces its commitment to delivering trustworthy pharmaceutical solutions. By prioritizing quality at every stage, Kwality Pharmaceuticals strives to earn the confidence of healthcare professionals and patients alike, solidifying its position as a reliable partner in healthcare.
Company Details
Key Leadership
KPL Share Price: Frequently Asked Questions
What is the current share price of Kwality Pharmaceuticals Limited?
Kwality Pharmaceuticals Limited (KPL) trades at ₹3356.00 on NSE and BSE. Market cap ₹2.81K (Cr). Educational data only.
What is the P/E ratio of Kwality Pharmaceuticals Limited?
Kwality Pharmaceuticals Limited has a P/E of 41.35x vs industry average 34.89x.
What is the Bull Run score for Kwality Pharmaceuticals Limited?
Kwality Pharmaceuticals Limited has a Bull Run score of 66.1/100 based on 25+ financial parameters.
Does Kwality Pharmaceuticals Limited pay dividends?
Kwality Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kwality Pharmaceuticals Limited?
Kwality Pharmaceuticals Limited has ROE of 22.82%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kwality Pharmaceuticals Limited?
Kwality Pharmaceuticals Limited has debt-to-equity of 0.39.
Is Kwality Pharmaceuticals Limited a good investment?
Bull Run gives Kwality Pharmaceuticals Limited a score of 66.1/100. This is not investment advice — consult a SEBI-registered advisor.